

Assessing the Human Gut Microbiota in Metabolic Disease

Jens Nielsen

Department of Chemical and Biological Engineering, Chalmers University of Technology, Sweden

Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Denmark

Science for Life Laboratory, Royal Institute of Technology, Sweden



Genome-scale Metabolic Models

We have reconstructed a comprehensive model (GEM) for human metabolism HMR2.0 and this is used for analysis of tissue specific metabolism

Reactions	Metabolites	Genes
8170	5998 (3160)*	3763

* Unique metabolites





We are combining this with GEMs for the gut microbiome to obtain a complete description of human metabolism



GEMs for 32 Tissues and Organs



Using RNAseq from 32 tissue biopsies we generated GEMs for 32 tissues and organs and identified unique metabolic functions for each tissue

RESEARCH ARTICLE

PROTEOMICS

Tissue-based n human proteoi

Mathias Uhlén,^{1,2,3}* Linn Fagerbe Per Oksvold,¹ Adil Mardinoglu,⁵ Å Anna Asplund,⁴ IngMarie Olsson,⁴ Cristina Al-Khalili Szigyarto,² Jac Jenny Ottosson Takanen,² Sophia

Science (2015) **347**:394

All models (including HMR2.0) are available through www.metabolicatlas.org

Holger Berling,² Hanna Tegel,² Jan Mulder,⁸ Johan Rockberg,² Peter Nilsson,¹ Jochen M Schwenk,¹ Marica Hamsten,² Kalle von Feilitzen,¹ Mattias Forsberg,¹ Lukas Persson,¹ Fredric Johansson,¹ Martin Zwahlen,¹ Gunnar von Heijne,⁹ Jens Nielsen,^{3,5} Fredrik Pontén⁴

Resolving the molecular details of proteome variation in the different tissues and organs of the human body will greatly increase our knowledge of human biology and disease. Here, we present a map of the human tissue proteome based on an integrated omics approach that involves quantitative transcriptomics at the tissue and organ level, combined with tissue microarray-based immunohistochemistry, to achieve spatial localization of proteins down to the single-cell level. Our tissue-based analysis detected more than 90% of the putative protein-coding genes. We used this approach to explore the human secretome, the membrane proteome, the druggable proteome, the cancer proteome, and the metabolic functions in 32 different tissues and organs. All the data are integrated in an interactive Web-based database that allows exploration of individual proteins, as well as navigation of global expression patterns, in all major tissues and organs in the human body. N-Acetyticiucosamine de novo sívrithesis Giuconeogenesis from Giyoenol Cerotic acid (complete oxidation) Lignocarate (complete oxidation) Lignocarate (complete oxidation) Ar P savage from Hypoxanthine Pentadecylic acid de novo synthesis Tridecylic acid de novo synthesis Margaric acid de novo synthesis 10Z-hentadocencic acid de novo synthesis Hentosacincic acid de novo synthesis Hentosacincic acid de novo synthesis Hentosacio cacid de novo synthesis Costenic de novo synthesis Hentosacio cacid de novo synthesis Costenic de novo synthesis Costenie de novo synthesis GSH de novo synthesis GSH de novo synthesis Homocystenie de novo synthesis Hentosacité de novo synthesis Castenie de novo synthesis Costenie de novo synthesis

Present metabolic function Absent metabolic function





Identification of sub-networks



From comparative analysis of 481 ccRCC samples and 71 tumor adjacent normal samples we identified 6 sub-networks

The second largest networks is responsible for the biosynthesis of chondroitin sulfate (CS) and heparan sulfate (HS)

PNAS (2014) 111:E866-E875; Cell Reports (2016) 15:1-15









From analysis of CS and HS in 34 patients with metastatic ccRCC and 16 controls we identified a prognostic biomarker.

Evaluation of the prognostic biomarker in validation cohort of 18 ccRCC patients and 9 healthy controls shows that it has very strong predictive strength



The Human Microbiome

- over 30,000 microbial genome projects (1995-2014)
 cover < 20% of the diversity of cultured archaeal and bacterial species represent just 15% of the overall known prokaryotic diversity.) ³
- The body contains 10 times more bacteria, archaea, fungi and other micro-organisms than human cells.







How to study the human microbiome? system



Total DNA extracted from fecal samples can be sequenced using NGD, e.g. with Illumina HiSeq2000



Very large data-sets are generated (Big-Data), typically 20 million reads per sample corresponding to >3 10⁹ basepairs Cohorts typically exceeds 100 subjects resulting in >3 10¹¹ basepairs



MEDUSA: Bioinformatics pipeline for **System** MEtagenomic Data UtiliSation and Analysis



Nature Comm. (2012) 3:1245; PLOS Comp. Biol. (2014) 10:e1003706



A global gut microbiome gene catalogue



- 11.7 million genes identified
- 9 million genes unique to a single study
- About 500,000 genes were core in all four studies
- 2.7 million genes shared between at least two studies

Shared genes were, however, the most abundant (with cores the most abundant)





PLOS Comp. Biol. (2014) 10:e1003706

Nature Comm. (2012) 3:1245

Patient T test p-value 0.173 10 CHALMERS

Gut Microbiome and Symptomatic Atherosclerosis

12 Patients

- Amaurosis fugax (3)
- Transient ischemic attack (4)
- Minor ischemic stroke (5)
- 15 Controls age and sex matched
- Serum chemistry (cholesterol, Triacylglycerides, HDL, LDL, inflammation markers ...)



Age

75 ω 20 ო 65 ŝ ß \sim 60 4 55 Control Patient Control Patient Control Patient T test p-value 0.26 T test p-value 0.0999 T test p-value 0.237 HDL LDL ApoA.I N ø 1.6 . . ŝ 4 4 4. ო 12 Control Patient Control Patient Control Patient T test p-value 0.0287 T test p-value 0.11 T test p-value 0.21 ApoB WBC CRP ÷ 9 4. 5 ω 1.0 ശ 0.6 Control Patient Control Patient Control T test p-value 0.233









CHALMERS

Atherosclerosis is associated with an altered gut micrbiota





Phytoene dehydrogenase is enriched in controls



High levels of lycopene and β -carotene are associated with a reduced risk of cardiovascular disease.





Nature Comm. (2012) **3**:1245

DIWA study



Large Swedish study on development of T2D in elderly women

	T2D (n=53)	IGT (n=49)	NGT (n=43)	P-value
Age	70	70	70	1
BMI	28.4±0.672	26.9±0.576	25.8±0.664	0.017
Waist	94.2±1.44	88.8±1.18	84.1±1.41	3.7e-06
HbA1c	5.52±0.1240	4.60±0.0508	4.53±0.0353	2.6e-16
Statin treatment, n (%)	26(49)	16(33)	10(23)	0.027
Insulin treatment, n (%)	6(11)	0(0)	0(0)	0.0044
Oral antidiabetic medication, n (%)	22(41)	0(0)	0(0)	1.7e-10

Type 2 diabetes mellitus (T2D)fasting glucose $\geq 6.1 \text{ mM}$ OR2H-OGTT $\geq 11.1 \text{ mM}$

Impaired glucose tolerance (IGT)fasting glucose < 6.1 mMANDNormal glucose tolerance (NGT)fasting glucose < 6.1 mMAND2H-OGTT < 7.8 mM

Nature (2013) **498**:99-103

Species abundance correlates with blood markers







CHALMERS

A working model for microbiota, system diet and host interactions



Metagenomics can identify associations and biomarkers, provide a catalogue of genes and generate hypotheses.

Modeling can generate and test hypotheses, provide detailed mechanistic understanding and be used as scaffold for data analyses.

Provide biomarkers and new interventions in the **medical field**

Aid in design of interventions in terms of drugs and probiotics in **pharmaceutical and food industry**



MicroObese Study



A study lead by Prof. Karine Clement identified that over-weight subjects have varied gut microbiome composition (Nature (2013) **500**:585-588



- Subjects with high gene count (HGC)
- Subjects with low gene count (LGC)

Low gene count suggests low bacterial diversity and LGC subjects had high HOMA index and other disease risk markers

Cell Metabolism Resource

Quantifying Diet-Induced Metabolic Changes of the Human Gut Microbiome

Saeed Shoaie,¹ Pouyan Ghaffari,¹ Petia Kovatcheva-Datchary,² Adil Mardinoglu,¹ Partho Sen,¹ Estelle Pujos-Guillot,³ Tomas de Wouters,⁴ Catherine Juste,⁴ Salwa Rizkalla,^{5,6} Julien Chilloux,⁷ Lesley Hoyles,⁷ Jeremy K. Nicholson,⁷ MICRO-Obes Consortium, Joel Dore,⁴ Marc E. Dumas,⁷ Karine Clement,^{5,6,8} Fredrik Bäckhed,^{2,9} and Jens Nielsen^{1,*}



6



MicroObese Study



Changes in the diet between HGC and LGC according to time points





CHALMERS



Abundance of the bacteria before and after diet interventions in HGC and LGC subjects







CHALMERS

Summary of average predictions for fecal metabolites at baseline and after 6 weeks





Cell Metabolism (2015) **22**:320-331

Also prediction of plasma metabolomics





<u>Cell Metabolism (2015)</u> 22:320-331



-0.5

0.5

Both groups observe a decrease in plasma amino acids in response to diet intervention

LGC subjects have a larger relative reduction in plasma amino acid levels compared with the HGC subjects



Using GEMs to study interaction susible between all key gut microbes



We used metagenomics data from:

- HMP (USA)
- MetaHIT(Denmark)
- China
- Sweden

to identify key species abundance



Relative species abundance



Selected Genomes for Model Reconstruction



113 species were identified to be of high abundance (>0.01%) in all four studies

107 are available in the SEED database and these were analyzed further





Metabolic complementarity analysis





Indicates that competition, not cooperation, dominates metabolic interaction between gut microbes.

Metabolic Complementarity Index

0.6

0.4

Metabolic Complementarity Index

0.0

0.2



Improving Child Growth

We are collaborating with **Bill & Melinda Gates Foundation** for using our GEMs for finding innovative solutions to the problem of child development in Africa.

We are analyzing how metabolism responds to nutrition and **malnutrition in children.**







CHALMERS



Bill& Melinda

GATES foundation



Prospects for Personalized Medicine



Use of gut metagenomics for stratification

 e.g. for responders and non-responders to immuno-therapies in cancer treatment

Development of second-generation probiotics for disease treatment

- T2D diabetes
- Combination drugs for cancer treatment

As for early days in human genomics we are still only learning, but we may see new therapies within the next 3-5 years



Acknowledgement

Francesco Gatto Adil Mardinoglu Fredrik Karlsson Saeed Shoaei Ibrahim El-Semman Boyang Ji

Collaborators:

Fredrik Bäckhed, GU (Sweden) Karine Clement, ICAN (France) Marc Dumas, ICL (UK)





27